Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC)
Head and neck squamous cell carcinoma (HNSCC) is the most common malignancy group in India and several other low- and middle-income countries. Currently, majority of the patients present in advanced stage where systemic therapy is standard of care. Multiple relapses are also not uncommon. Almost all...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2025-01-01
|
| Series: | South Asian Journal of Cancer |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1791783 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849392825929564160 |
|---|---|
| author | Purvish M. Parikh Ghanashyam Biswas Nilesh Ashok Dhamne Chetan Dilip Deshmukh Sewanti Limaye Ashish Singh Hemant Malhotra Viashsta Pankaj Maniar Bhupendra Nath Kapur Prasad V.S.S. Sripada Vikas Tulsidas Talreja Poonam Patil Suhas Vilasrao Agre Amit Dilip Bhat Priya Privadarshini Nayak Arun Seshachalam Boman Nariman Dhabhar Ajay Sharma Niraj N. Bhatt Pratap Kishore Das Atul Sharma Govind Babu Kanakasetty Suresh Hariram Advani |
| author_facet | Purvish M. Parikh Ghanashyam Biswas Nilesh Ashok Dhamne Chetan Dilip Deshmukh Sewanti Limaye Ashish Singh Hemant Malhotra Viashsta Pankaj Maniar Bhupendra Nath Kapur Prasad V.S.S. Sripada Vikas Tulsidas Talreja Poonam Patil Suhas Vilasrao Agre Amit Dilip Bhat Priya Privadarshini Nayak Arun Seshachalam Boman Nariman Dhabhar Ajay Sharma Niraj N. Bhatt Pratap Kishore Das Atul Sharma Govind Babu Kanakasetty Suresh Hariram Advani |
| author_sort | Purvish M. Parikh |
| collection | DOAJ |
| description | Head and neck squamous cell carcinoma (HNSCC) is the most common malignancy group in India and several other low- and middle-income countries. Currently, majority of the patients present in advanced stage where systemic therapy is standard of care. Multiple relapses are also not uncommon. Almost all HNSCC tumors have epidermal growth factor receptor (EGFR) overexpression, making an attractive target. Cetuximab is the most successful method to target EGFR in HNSCC. After decades of its use, it still is a prominent part of the current management guidelines. Since other agents have also been proven to be useful, we felt it was necessary to develop a real-world consensus guideline to help the decision-making process among the community oncologists. Our expert committee therefore put together currently available data, insights from their real-world clinical practice, and voted to arrive at a consensus. These consensus guidelines represent how cetuximab should be used today in the management of HNSCC. |
| format | Article |
| id | doaj-art-5144ff3764c74bb8959bb6d498c825d8 |
| institution | Kabale University |
| issn | 2278-330X 2278-4306 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | South Asian Journal of Cancer |
| spelling | doaj-art-5144ff3764c74bb8959bb6d498c825d82025-08-20T03:40:41ZengThieme Medical and Scientific Publishers Pvt. Ltd.South Asian Journal of Cancer2278-330X2278-43062025-01-01140109010210.1055/s-0044-1791783Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC)Purvish M. Parikh0Ghanashyam Biswas1Nilesh Ashok Dhamne2Chetan Dilip Deshmukh3Sewanti Limaye4Ashish Singh5Hemant Malhotra6https://orcid.org/0000-0001-5613-5375Viashsta Pankaj Maniar7Bhupendra Nath Kapur8Prasad V.S.S. Sripada9Vikas Tulsidas Talreja10https://orcid.org/0000-0002-1599-3047Poonam Patil11https://orcid.org/0000-0001-9518-2609Suhas Vilasrao Agre12Amit Dilip Bhat13Priya Privadarshini Nayak14Arun Seshachalam15Boman Nariman Dhabhar16Ajay Sharma17Niraj N. Bhatt18Pratap Kishore Das19Atul Sharma20Govind Babu Kanakasetty21https://orcid.org/0000-0002-1303-2226Suresh Hariram Advani22Department of Clinical Hematology, Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, IndiaDepartment of Medical Oncology, Sparsh Hospitals and Critical Care Pvt Ltd, Bhubaneswar, Orissa, IndiaDepartment of Medical Oncology, Kolhapur Cancer Center, Kolhapur, Maharashtra, IndiaDepartment of Medical Oncology, Deenanath Mangeskar Hospital, Pune, Maharashtra, IndiaDepartment of Medical and Precision Oncology, Sir H.N. Reliance Foundation Hospital, Mumbai, Maharashtra, IndiaDepartment of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu, IndiaDepartment of Medical Oncology, Sri Ram Cancer Center, Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, IndiaDepartment of Medical Oncology, MOC Cancer Care and Research Center, Mumbai, Maharashtra, IndiaDepartment of Medical Oncology, Yashoda Hospital, Ghaziabad, Uttar Pradesh, IndiaDepartment of Medical Oncology, Apollo Cancer Centers, Hyderabad, Telangana, IndiaDepartment of Medical Oncology, Regency Hospital, Kanpur, Uttar Pradesh, IndiaDepartment of Medical Oncology, Manipal Hospital, Bengaluru, Karnataka, IndiaDepartment of Medical Oncology, Hirandani Hospital, Mumbai, Maharashtra, IndiaDepartment of Medical Oncology, Avinash Cancer Clinic, Pune, Maharashtra, IndiaDepartment of Medical Oncology, Sum Ultimate Medicare, Bhubaneswar, Orissa, IndiaDepartment of Medical Oncology, Dr GVN Cancer Institute, Trichy, Kerala, IndiaDepartment of Medical Oncology, Fortis Mulund, Mumbai, Maharashtra, IndiaDepartment of Medical Oncology, AS lifeline Cancer Care Hospital, New Delhi, IndiaDepartment of Medical Oncology and Hematology, Hemato Oncology Clinic, Vadodara, Gujarat, IndiaDepartment of Medical Oncology, Apollo Hospital, New Delhi, IndiaDepartment of Medical Oncology, Max Hospital Saket, New Delhi, IndiaDepartment of Medical Oncology, St. Johns Medical College Hospital, Bengaluru, Karnataka, IndiaDepartment of Medical Oncology, Sushruth Hospital, Mumbai, Maharashtra, IndiaHead and neck squamous cell carcinoma (HNSCC) is the most common malignancy group in India and several other low- and middle-income countries. Currently, majority of the patients present in advanced stage where systemic therapy is standard of care. Multiple relapses are also not uncommon. Almost all HNSCC tumors have epidermal growth factor receptor (EGFR) overexpression, making an attractive target. Cetuximab is the most successful method to target EGFR in HNSCC. After decades of its use, it still is a prominent part of the current management guidelines. Since other agents have also been proven to be useful, we felt it was necessary to develop a real-world consensus guideline to help the decision-making process among the community oncologists. Our expert committee therefore put together currently available data, insights from their real-world clinical practice, and voted to arrive at a consensus. These consensus guidelines represent how cetuximab should be used today in the management of HNSCC.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1791783oral cancermonoclonal antibodyEGFRtargeted therapy |
| spellingShingle | Purvish M. Parikh Ghanashyam Biswas Nilesh Ashok Dhamne Chetan Dilip Deshmukh Sewanti Limaye Ashish Singh Hemant Malhotra Viashsta Pankaj Maniar Bhupendra Nath Kapur Prasad V.S.S. Sripada Vikas Tulsidas Talreja Poonam Patil Suhas Vilasrao Agre Amit Dilip Bhat Priya Privadarshini Nayak Arun Seshachalam Boman Nariman Dhabhar Ajay Sharma Niraj N. Bhatt Pratap Kishore Das Atul Sharma Govind Babu Kanakasetty Suresh Hariram Advani Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC) South Asian Journal of Cancer oral cancer monoclonal antibody EGFR targeted therapy |
| title | Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| title_full | Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| title_fullStr | Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| title_full_unstemmed | Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| title_short | Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| title_sort | practical consensus guidelines on the use of cetuximab in head and neck squamous cell carcinoma hnscc |
| topic | oral cancer monoclonal antibody EGFR targeted therapy |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1791783 |
| work_keys_str_mv | AT purvishmparikh practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT ghanashyambiswas practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT nileshashokdhamne practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT chetandilipdeshmukh practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT sewantilimaye practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT ashishsingh practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT hemantmalhotra practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT viashstapankajmaniar practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT bhupendranathkapur practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT prasadvsssripada practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT vikastulsidastalreja practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT poonampatil practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT suhasvilasraoagre practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT amitdilipbhat practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT priyaprivadarshininayak practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT arunseshachalam practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT bomannarimandhabhar practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT ajaysharma practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT nirajnbhatt practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT pratapkishoredas practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT atulsharma practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT govindbabukanakasetty practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc AT sureshhariramadvani practicalconsensusguidelinesontheuseofcetuximabinheadandnecksquamouscellcarcinomahnscc |